Current Treatment Research
NIH is supporting many clinical trials through its ACTIV initiative to test a variety of treatments and therapies for COVID-19.
This study tests the safety and effectiveness of three medicines, called immune modulators, to minimize the effects of an overactive immune system response that some COVID-19 patients experience. This response, called a “cytokine storm,” can lead to acute respiratory distress syndrome, multiple organ failure, and other life-threatening complications. The clinical trial aims to determine if minimizing that immune response can reduce the need for ventilators and shorten hospital stays.
This clinical trial is enrolling adults with COVID-19 who are not hospitalized to evaluate safety, to understand if the treatment can reduce the duration of symptoms, and to test if the treatment can increase the proportion of participants with undetectable virus.
Three types of studies aim to determine if various types of medicines called blood thinners can treat adults diagnosed with COVID-19 and prevent life-threatening blood clots from forming. The studies focus on people who are diagnosed with COVID-19 but are not hospitalized, those who are hospitalized, and those who are recovering from COVID-19.
These studies are enrolling people who are hospitalized with COVID-19 to test whether medicines already approved to treat other conditions can be used to also treat COVID-19.
Learn about monoclonal antibodies, which are being tested in NIH clinical trials as a potential treatment for COVID-19.
Learn how antibodies can be effective at preventing COVID-19, especially for people with compromised immune systems.
Learn what to do if you’ve tested positive for COVID-19 and what approved treatments are being used.
Learn more about treatment options and clinical trials from HHS.
Clinical trials offer hope for patients while helping researchers find better treatments.
Selected NIH-Published Research on Treatments
Grobler, J. A., Anderson, A. S., Fernandes, P., Diamond, M. S., Colvis, C. M., Menetski, J. P., . . . Carter, K. L, on behalf of the ACTIV Preclinical Working Group. (2020). Accelerated preclinical paths to support rapid development of COVID-19 therapeutics. Cell Host and Microbe, 28(5), 636–645. doi:10.1016/j.chom.2020.09.017
Hewitt, J. A., Lutz, C., Florence, W. C., Pitt, M. L. M., Rao, S., Rappaport, J., & Haigwood, N.L., on behalf of the ACTIV Preclinical Working Group. (2020). ACTIVating resources for the COVID-19 pandemic: In vivo models for vaccines and therapeutics. Cell Host and Microbe, 28(5), 646–659. doi:10.1016/j.chom.2020.09.016
Collins, F. S., & Stoffels, P. (2020). Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An unprecedented partnership for unprecedented times. JAMA, 323(24), 2455–2457. doi:10.1001/jama.2020.8920